On January 23, 2026, Cencora announced a strategic partnership with Curant Rare designed to streamline commercialization of orphan and rare disease treatments for biotech sponsors. Under the agreement, Cencora will leverage its global pharmaceutical logistics network and market access services—spanning pharmacovigilance support, cold‐chain distribution and regulatory compliance—to integrate with Curant Rare’s specialty pharmacy infrastructure and omnichannel patient engagement platform. The collaboration establishes a single‐source supply chain solution, reducing average time‐to‐therapy by an estimated 15% and cutting end‐to‐end clinical distribution costs by up to 10%. Sponsors will gain real‐world evidence insights via patient‐reported outcomes collected through Curant Rare’s Medication Care Management® system, enabling accelerated market entry across North America and Europe.

Effective January 20, 2026, Cencora elected Ellen Cooper—Chairman, President and CEO of Lincoln Financial—as an independent director. Ms. Cooper brings over 25 years of leadership in asset management, risk oversight and regulatory strategy, having served as EVP and CIO at Lincoln prior to her current role, and as Global Head of Insurance Strategy at Goldman Sachs Asset Management. Her appointment expands the board to 12 members and underscores Cencora’s focus on financial governance and enterprise risk management. Cencora’s Chair, Mark Durcan, noted that Cooper’s actuarial credentials and tenure on the Executive Committee of the American Council of Life Insurers will strengthen oversight as the company scales its $300 billion annual revenue operations and integrates new commercial programs in specialty and rare disease markets.